《科创板日报》10月20日讯 今日科创板早报主要内容有：力箭一号遥八运载火箭发射成功；优必选人 形机器人中标亿元订单；沐曦股份将于10月24日上会。 我国生成式人工智能用户规模超5亿 中国互联网络信息中心在2025（第六届）中国互联网基础资源大会上发布《生成式人工智能应用发展报 告（2025）》。报告显示，截至2025年6月，我国生成式人工智能用户规模达5.15亿人，较2024年12月 增长2.66亿人，用户规模半年翻番；普及率为36.5%。 《科创板日报》主播小K为您播报。 市场动态 科技部部长阴和俊主持召开"十五五"国家科技创新发展工作地方、部门座谈会 科技部党组书记、部长阴和俊10月11日、17日主持召开"十五五"国家科技创新发展工作地方、部门座谈 会，听取相关地方、部门关于"十五五"时期科技强国建设思路目标、任务举措的意见建议。阴和俊指 出，"十五五"时期是推动科技强国建设的关键攻坚期，把握新一轮科技革命和产业变革机遇、应对复杂 多变国际形势、支撑高质量发展，对科技工作提出了更高要求。准确把握"十五五"时期的阶段性特征， 充分调动各方面力量，科学谋划好"十五五"时期科技创新发展思路目标和任务举措，对加 ...

Core Insights - The 2025 European Society for Medical Oncology (ESMO) conference will take place in Berlin from October 17 to 21, with several domestic companies planning to disclose data [1] - Zai Lab (688266) will present clinical research data for its new drugs Alveltamig (ZG006) and Nilvanstomig (ZG005) at ESMO [1] - ZG006 is the world's first tri-specific antibody targeting DLL3, showing potential as a best-in-class molecule with significant and durable anti-tumor efficacy in SCLC or NEC patients who have failed existing standard treatments [1] - ZG005 is a recombinant humanized anti-PD-1/TIGIT bispecific antibody, expected to treat various solid tumors, and is among the first of its kind to enter clinical research globally [1] Company Developments - Zai Lab reported that ZG005 combined with chemotherapy shows good safety and efficacy in patients with advanced neuroendocrine carcinoma, supporting further clinical research [2] - Aosaikang (002755) announced the presentation of data for its new cMET inhibitor ASKC202 combined with Lapatinib for locally advanced or metastatic non-small cell lung cancer, demonstrating good safety and high tumor response rates [2] - Aosaikang's Lapatinib is its third-generation EGFR TKI, and the company believes that the synergy of its two innovative drug projects will enhance its oncology product pipeline [2] Other Company Announcements - Maiwei Biotech (688062) plans to report data on its B7-H3 targeted antibody-drug conjugate 7MW3711 for advanced solid tumors at ESMO [3] - Kelun Pharmaceutical (002422) will present a study comparing the efficacy and safety of Trastuzumab deruxtecan versus Emicizumab in HER2-positive patients who have previously received Trastuzumab and taxane treatments [3] - Academic conferences are crucial catalysts for innovative drug sectors, with major events like ASCO, ESMO, and WCLC being the most significant in the oncology field [3]

Core Insights - The company announced that clinical research data and latest progress for its self-developed drugs Alveltamig (code: ZG006) and Nilvanstomig (code: ZG005) will be presented at the European Society for Medical Oncology (ESMO) annual meeting scheduled from October 17 to 21, 2025 [1] Drug Development - ZG006 is the world's first tri-specific antibody targeting the DLL3 target (DLL3×DLL3×CD3), representing a first-in-class molecular form with the potential to become a best-in-class molecule [1] - ZG005 is one of the first drugs to enter clinical research targeting the same mechanism, with no similar mechanism drugs approved for market globally [1]

Core Viewpoint - The company announced that clinical research data and latest progress for its self-developed drugs Alveltamig (ZG006) and Nilvanstomig (ZG005) will be presented at the CSCO Annual Meeting from September 10 to 14, 2025 [1] Group 1: ZG006 Clinical Data - ZG006 has shown promising results in a Phase II dose-optimization clinical study for patients with refractory advanced small cell lung cancer, with a total of 60 patients included in the analysis as of May 12, 2025 [1] - The best overall response rates (ORR) for the 10 mg Q2W and 30 mg Q2W groups were 60.0% and 63.3% respectively, with confirmed response rates of 53.3% for both groups [1] - Disease control rates (DCR) were reported at 73.3% for the 10 mg Q2W group and 70.0% for the 30 mg Q2W group [1] Group 2: ZG005 Clinical Data - ZG005, in combination with Etoposide and Cisplatin, has been evaluated in a Phase I/II clinical study for first-line treatment of advanced neuroendocrine carcinoma, with 84 patients enrolled as of August 21, 2025 [1] - Among the 60 patients who could be assessed for efficacy, the ORR was reported at 43.8%, 63%, and 29.4% [1]